Skin Pathologies

PARP inhibitors are promising therapeutic approach for skin pathologies. Alfa Cytology, has a deep understanding of the role of PARP (poly(ADP-ribose) polymerase) in skin biology and its potential as a therapeutic target. We are dedicated to exploring the potential of PARP inhibitors for the treatment of skin pathologies.

PARP as a Therapeutic Target for Skin Pathologies

PARP-1 (poly (ADP-ribose) polymerase-1) is a key enzyme involved in the cellular response to DNA damage caused by excessive UV radiation, which can lead to skin injuries. Its activation in response to UV exposure triggers inflammation and further tissue damage, exacerbating conditions like sunburn and increasing skin cancer risk. PARP inhibitors offer a promising therapeutic approach for managing UV-induced skin injuries by reducing inflammation, protecting against DNA damage, and restoring cellular energy levels. Ongoing research aim to evaluate the safety and efficacy of these therapies in treating skin pathologies related to UV exposure.

Fig. 1 An overview of the PARP-mediated pathologies of skin pathologies. (Purohit N., et al. 2020)

PARP Inhibitor Development for Skin Pathologies

By targeting PARP-1, PARP inhibitors have demonstrated the ability to mitigate the detrimental effects of UV-induced skin injury, reducing inflammation, improving skin barrier function, and promoting tissue repair. Moreover, PARP inhibitors have shown promise in the management of other skin conditions, such as psoriasis and atopic dermatitis. In these inflammatory skin disorders, PARP-1 has been implicated in the dysregulation of immune responses and the perpetuation of chronic inflammation. PARP inhibitors have been observed to modulate key inflammatory pathways, suppress the production of pro-inflammatory mediators, and restore the balance of the skin's immune system.

Our Services

At Alfa Cytology, we offer comprehensive preclinical services to support the development of PARP inhibitor-based therapies for skin pathologies. Our experienced team of researchers and scientists collaborate closely with clients to design and execute robust in vitro and in vivo studies, ensuring the scientific rigor of the data generated.

By Disease

By Service

At Alfa Cytology, we are dedicated to advancing the field of PARP inhibitor research for skin pathologies. Our comprehensive preclinical services and strong scientific expertise position us as a trusted partner for pharmaceutical and biotechnology companies seeking to develop innovative, evidence-based PARP inhibitor-based therapies for skin conditions. For more information about our PARP inhibitor development program for metabolic disease or to discuss potential collaborations, please don't hesitate to contact us.

For research use only. Not intended for any clinical use.